diabetic nephropathy. With renal complications Diabetic nephropathy
Conditions
Interventions
Intervention 1: Control group: Receiving 1 placebo containing Miglyol oil weekly for 8 weeks. Intervention 2: Intervention group: Receiving vitamin D3 supplement which contains 50,000 IU Pearl vitami
Placebo
Treatment - Drugs
Control group: Receiving 1 placebo containing Miglyol oil weekly for 8 weeks.
Intervention group: Receiving vitamin D3 supplement which contains 50,000 IU Pearl vitamin D3 cholecalciferol weekly for 8 weeks.
Sponsors
Vice chancellor for research, Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: aged between 20 to 50 years; have type 2 diabetes; control blood glucose less than 140 mg / dl; With BMI 20-35; stage 3 nad 4 diabetic nephropathy; albuminuria more than 30 mg per day; lack of proven vitamin D levels over 15 ng / l and less than 30 ng / l; Do not use calcium supplements and vitamin D in the last 3 months; Not taking medications that affect vitamin D metabolism, such as parathyroid hormone, estrogen, and calcitonin; willingness to cooperate Exclusion criteria: Changing the dose of the blood glucose lowering drugs; Change of medication or other treatment; taking calcium and vitamin D supplements during the study; with glomerulonephritis; Phosphorus more than 2/5 mg / dl; corrected calcium more than 10 mg / dl; active malignancy; The possibility of requiring renal replacement over the next year; uncontrolled high blood pressure; Taking antacids containing magnesium; Thiazide diuretics consumption; unwillingness to participate or to continue working
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Albuminuria. Timepoint: Before and after intervention (8 weeks). Method of measurement: Measurement of Albumin in urin by using kits.;Fasting blood glucose. Timepoint: Before and after intervention (8 weeks). Method of measurement: Measurement of fasting blood glucose by using kits.;Hemoglobin A1c. Timepoint: Before and after intervention (8 weeks). Method of measurement: Using ion exchange chromatography.;Insulin. Timepoint: Before and after intervention (8 weeks). Method of measurement: Elisa.;TNF-a. Timepoint: Before and after intervention (8 weeks). Method of measurement: Elisa.;Interlukin6. Timepoint: Before and after intervention (8 weeks). Method of measurement: Elisa.;Added at 2016-02-16: Catalase activity. Timepoint: Added at 2016-02-16: Before and after intervention (8 weeks). Method of measurement: Added at 2016-02-16: AEBI with using a UV/visbile spectrophotometer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure. Timepoint: Before and after intervention (8 weeks). Method of measurement: pressure indicator. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAsra Esfandiari
Faculty of Nutrition,Tabriz University of Medical Sciences,Tabriz
Outcome results
None listed